title: Comparison of treatment planning parameters for dose painting head and neck plans delivered with tomotherapy.
abstract: OBJECTIVE
  The aim of this study was to determine which physical delivery parameter changes are most suitable for multiple-level dose-painting treatment plans with helical tomotherapy (HT).
  
  
  METHODS
  A total of 96 treatment plans were generated for 12 patients who had undergone fluorine-18 fludeoxyglucose positron emission tomography/CT ((18)F-FDG-PET/CT) scan to plan head and neck cancer treatment. Based on these PET-CT images, the dose was escalated to 96 Gy in 32 fractions as a function of PET intensity values. The intensity-based prescription was converted into seven discrete dose levels. For the same patient, different HT plans were optimized by varying parameters such as field width (FW), pitch (PF) and modulation factor (MF). Dose conformity was evaluated using quality-volume histograms, quality factors (QFs), weighted index of achievement (IOAw), coldness (IOCw) and hotness (IOHw). Moreover, doses to organs at risk (OARs), target volumes and execution time were analyzed.
  
  
  RESULTS
  Median QFs were the best for FW = 1.05 cm (QF = 2.10) and the worst for FW = 2.5 cm (QF = 3.04). The same trend was observed for IOAw, IOCw and IOHw. Combination of FW = 1.05 cm and MF = 5 leads to the longest beam-on time (above 25 min), whereas FW = 2.5 cm and MF = 3 lead to the shortest time (below 8 min). Data analyzed based on dose-volume histogram showed that changes in FW had the strongest impact on plan quality, whereas the effect of MF and PF changes was moderate.
  
  
  CONCLUSIONS
  HT is suitable for multiple-level dose-painting treatment plans.
  
  
  CONCLUSIONS
  Changes in FW and MF had the greatest impact on dose distribution quality and beam-on time. Changes in PF only influenced doses to the OARs.
authors.affiliation: 1 Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Skórska
authors.affiliation: 1 Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.|2 Department of Electroradiology, University of Medical Sciences, Poznan, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Piotrowski
authors.affiliation: 1 Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.
authors.forename: Adam
authors.initials: A
authors.lastname: Ryczkowski
authors.affiliation: 2 Department of Electroradiology, University of Medical Sciences, Poznan, Poland.|3 Department of Radiotherapy II, Greater Poland Cancer Centre in Poznan, Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Kaźmierska
mesh_terms: D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D059351:Organ Sparing Treatments / Q000379:methods; D010347:Patient Care Planning; D049268:Positron-Emission Tomography / Q000379:methods; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D012189:Retrospective Studies
references.citation: Radiat Oncol. 2015 Sep 17;10:191
references.pmid: 26377574
references.citation: Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1045-55
references.pmid: 20643512
references.citation: Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):285-9
references.pmid: 9226314
references.citation: Cancer Res. 1996 Oct 1;56(19):4509-15
references.pmid: 8813149
references.citation: Med Phys. 2004 Jun;31(6):1452-61
references.pmid: 15259648
references.citation: Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):126-35
references.pmid: 17448871
references.citation: J Appl Clin Med Phys. 2014 Jul 08;15(4):4941
references.pmid: 25207424
references.citation: Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):333-42
references.pmid: 16414369
references.citation: Rep Pract Oncol Radiother. 2015 Jan 18;20(2):145-52
references.pmid: 25859405
references.citation: Strahlenther Onkol. 2012 Jan;188(1):97-9
references.pmid: 22234506
references.citation: Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1266-73
references.pmid: 19910128
references.citation: Radiother Oncol. 2000 Aug;56(2):135-50
references.pmid: 10927132
references.citation: Acta Oncol. 2015 Feb;54(2):253-60
references.pmid: 24991892
references.citation: Radiother Oncol. 1996 Oct;41(1):31-9
references.pmid: 8961365
references.citation: Rep Pract Oncol Radiother. 2014 Dec 16;20(2):104-12
references.pmid: 25859399
references.citation: Radiother Oncol. 2006 Jun;79(3):249-58
references.pmid: 16564588
references.citation: J Cancer Res Ther. 2013 Oct-Dec;9(4):618-23
references.pmid: 24518706
references.citation: Adv Exp Med Biol. 1994;345:445-50
references.pmid: 8079741
references.citation: Radiol Oncol. 2012 Dec;46(4):328-36
references.pmid: 23412761
references.citation: Radiother Oncol. 2011 Sep;100(3):402-6
references.pmid: 21937139
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):551-60
references.pmid: 10837935
references.citation: Rep Pract Oncol Radiother. 2014 Nov 18;20(2):99-103
references.pmid: 25859398
references.citation: Acta Oncol. 2010 Oct;49(7):964-71
references.pmid: 20831483
references.citation: Med Dosim. 2011 Winter;36(4):397-403
references.pmid: 21377865
references.citation: Acta Oncol. 2010 Oct;49(7):991-6
references.pmid: 20831487